Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

291.43 +6.12 (+2.15%)
Streaming Delayed Price Updated: 1:44 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 536,127
Open 287.44
Bid (Size) 291.24 (1)
Ask (Size) 291.67 (1)
Prev. Close 285.31
Today's Range 285.41 - 296.80
52wk Range 146.79 - 304.39
Shares Outstanding 118,847,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress
From Alnylam Pharmaceuticals, Inc.
Via Business Wire

Performance

YTD
+24.7%
+24.7%
1 Month
+25.2%
+25.2%
3 Month
+16.6%
+16.6%
6 Month
+25.5%
+25.5%
1 Year
+94.0%
+94.0%

More News

Read More
Earnings Scheduled For May 1, 2025
Via Benzinga
$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk
Via Benzinga
Topics World Trade
Exposures Tariff
Apple To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
$100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
These 3 Funds Offer Sky-High Yields of 15% or More and Trade at a Discount
Via The Motley Fool
BridgeBio's Pfizer-Rivaling Heart Drug Just Obliterated Sales Expectations
Via Investor's Business Daily
Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
How Do Investors Really Feel About Alnylam Pharmaceuticals?
Via Benzinga
Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 15 Years
Via Benzinga
Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
Is Alnylam Pharmaceuticals Gaining or Losing Market Support?
Via Benzinga
Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
27 Analysts Assess Alnylam Pharmaceuticals: What You Need To Know
Via Benzinga
If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today
Via Benzinga
FDA Approves Sanofi's Hemophilia Drug
Via Benzinga
Exposures Product Safety
Competitive Analysis In The ATTR-CM Field
Via Talk Markets
Topics Stocks / Equities
Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology’s Annual Scientific Session 2025
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades Stock
Via Benzinga
Exposures Product Safety

Frequently Asked Questions

Is Alnylam Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Alnylam Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Alnylam Pharmaceuticals, Inc. - Common Stock trade on?
Alnylam Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock is ALNY on the Nasdaq Stock Market
What is the current price of Alnylam Pharmaceuticals, Inc. - Common Stock?
The current price of Alnylam Pharmaceuticals, Inc. - Common Stock is 291.43
When was Alnylam Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Alnylam Pharmaceuticals, Inc. - Common Stock was at 05/19/25 01:44 PM ET
What is the market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock is 34.64B
How many shares of Alnylam Pharmaceuticals, Inc. - Common Stock are outstanding?
Alnylam Pharmaceuticals, Inc. - Common Stock has 35B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.